News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019
MOUNTAIN VIEW, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market close on Monday, March 11, 2019 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 10:30 a.m.
View HTML
Toggle Summary ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019
-- Companies plan to file for full marketing approval to EMA and FDA in 2020 -- MOUNTAIN VIEW, Calif. and ZURICH, Switzerland, Jan. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd. , a company of Vifor Pharma Group , today announced that in light of
View HTML
Toggle Summary ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 1:30 p.m. PST .
View HTML
Toggle Summary ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo -- -- Company’s studies also show CCR4 inhibition enhances effectiveness of checkpoint inhibition in tumor models in vivo -- MOUNTAIN VIEW, Calif.
View HTML
Toggle Summary ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference
MOUNTAIN VIEW, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 8:30 a.m. ET .
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights
-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 – -- $186 million in cash and investments at September 30, 2018 -- -- Received Orphan Drug Designation for CCX140 in Focal Segmental Glomerulosclerosis (FSGS) -- -- Conference call today
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018
MOUNTAIN VIEW, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis -- -- Reveals Potential New Role for Chemokine Receptor 2 (CCR2) in the Treatment of Focal Segmental Glomerulosclerosis (FSGS) with First
View HTML
Toggle Summary ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
View HTML